Skip to main content

Table 3 Base Case results (ref. Remdesivir)

From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

Strategy

Δ Cost

Δ QALY

ICER

Remdesivir

ref.

ref.

 

Dexamethasone

1201.3

0.0295

40735.2

Rem + Dex

185.8

0.0356

5221.9

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us